# SERENA-2 (NCT04214288)

> A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04214288
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Advanced ER-Positive HER2-Negative Breast Cancer
- Interventions: AZD9833; Fulvestrant
- Enrollment: 240
- Primary outcome: Progression-free Survival (PFS)

## Commentary we found

- YouTube: 69
- Podcasts: 51
- X threads: 16

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=serena-2-nct04214288

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04214288", "email": "<work email>"}; the inbox owner confirms by the emailed link.